semaglutide concerns A new study is raising about GLP-1 weight loss drugs and eating disorders. Researchers found that 32% of patients with eating disorders report having used a weight loss injection at least Research Reveals Potential Risks of

Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, et al

As such, and reviewing the class purely on its glucose-lowering effect, NICE has continued recommending a BMI cut-off for starting a GLP-1 RA of 35 kg/m 2 , unless insulin therapy would have significant occupational implications or weight loss would improve other significant obesity-related comorbidities

Not all GLP-1s behaved the same: One study of exendin-4 (exenatide) in mice found no drop in birth weight and even showed increased early growth, highlighting how inconsistent animal results can be

Ozempic breath may be the street name for the condition, but scientists actually use the term drug-related halitosis, according to a study in the International Dental Journal

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Wharton S., Blevins T., Connery L., Rosenstock J., Raha S., Liu R., Ma X., Mather K.J., Haupt A., Robins D., et al